ClinVar Miner

Submissions for variant NM_014363.6(SACS):c.13132C>T (p.Arg4378Ter)

dbSNP: rs747868017
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 5
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Labcorp Genetics (formerly Invitae), Labcorp RCV001865265 SCV002243937 pathogenic Spastic paraplegia 2024-10-17 criteria provided, single submitter clinical testing This sequence change creates a premature translational stop signal (p.Arg4378*) in the SACS gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 202 amino acid(s) of the SACS protein. This variant is present in population databases (rs747868017, gnomAD 0.0009%). This premature translational stop signal has been observed in individuals with spastic ataxia of Charlevoix-Saguenay (PMID: 20852969, 30638817). ClinVar contains an entry for this variant (Variation ID: 370756). This variant disrupts a region of the SACS protein in which other variant(s) (p.Tyr4538*) have been determined to be pathogenic (internal data). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic.
3billion RCV000410263 SCV002521153 likely pathogenic Charlevoix-Saguenay spastic ataxia 2022-05-22 criteria provided, single submitter clinical testing The variant is observed at an extremely low frequency in the gnomAD v2.1.1 dataset (total allele frequency: <0.001%). Stop-gained (nonsense): predicted to result in a loss or disruption of normal protein function through protein truncation. The predicted truncated protein may be shortened by less than 10%. The variant has been reported to be in trans with a pathogenic variant as either compound heterozygous or homozygous in at least 2 similarly affected unrelated individuals (PMID: 30638817). The variant has been reported to be associated with SACS related disorder (ClinVar ID: VCV000370756 / PMID: 20852969). Therefore, this variant is classified as likely pathogenic according to the recommendation of ACMG/AMP guideline.
PROSPAX: an integrated multimodal progression chart in spastic ataxias, Center for Neurology; Hertie-Institute for Clinical Brain Research RCV000410263 SCV005061928 likely pathogenic Charlevoix-Saguenay spastic ataxia 2022-01-01 criteria provided, single submitter research
Fulgent Genetics, Fulgent Genetics RCV000410263 SCV005632149 pathogenic Charlevoix-Saguenay spastic ataxia 2024-01-30 criteria provided, single submitter clinical testing
Counsyl RCV000410263 SCV000486150 likely pathogenic Charlevoix-Saguenay spastic ataxia 2016-04-12 no assertion criteria provided clinical testing This submission and the accompanying classification are no longer maintained by the submitter. For more information on current observations and classification, please contact variantquestions@myriad.com.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.